|
|
|
|
|
|
|
|
Blogger's Note: this abstract does not indicate what form of RT (eg. targeted/WAR); it also does not discuss longterm side effects/complications/adverse effects (eg. vs OS)
abstract:
Impact on Survival With Adjuvant Radiation Therapy for Clear Cell, Mucinous, and Endometriod Ovarian Cancer: The SEER Experience From 2004 to 2011 - International Journal of Radiation Oncology • Biology • Physics
Purpose/Objective(s)
To
evaluate the impact of radiation therapy (RT) on cause-specific and
overall survival for stage I-III clear cell, mucinous, and endometrial
ovarian cancer.
Materials/Methods
We
analyzed incidence, survival, and treatment data from the Surveillance,
Epidemiology, and End Results (SEER) Program from 2004 to 2011 for
clear cell, mucinous, and endometrial histologies of the ovary for
stages I-III. We examined cause-specific survival (CSS) and overall
survival (OS) for all 3 histologies combined and for each histology with
relation to the use of adjuvant RT. Survival analysis was calculated by
Kaplan-Meier and log-rank analysis.
Results
There
was a total of 13,313 cases of which 13,024 received no RT and 289
received RT. CSS was higher in individuals who did not receive RT at 5
years (81% vs 74%) and 10 years (74% vs 65%), P=.003. Similarly, OS was higher in individuals who did not receive RT at 5 years (76% vs 73%) and 10 years (64% vs 59%), P=.04. However, stage III patients who received RT had a higher OS at 5- (54% vs 44%) and 10-year intervals (36% vs 30%), P=.04.
For clear cell histology, there were a total of 3467 cases of which 68
received RT. OS was higher in individuals who received no RT compared to
those who received RT both at 5 years (71% vs 41%) and 10 years (61% vs
40%), P<.0001. For mucinous histology, there were a total
of 4369 cases of which 68 received RT. OS was higher in individuals who
received no RT at 5 years (76% vs 70%) and 10 years (65% vs 49%), P=.037.
In contrast, stage III patients with mucinous histology who received RT
had a higher OS at 5- (50% vs 36%) and 10-year intervals (45% vs 26%), P<.05.
For endometriod histology, there were a total of 7993 cases of which
314 received RT. OS was similar in these patients regardless of their RT
status at 5 years (78% vs 81%) and similar at 10 years (65% vs 65%), P=.97.
Conclusion
Over
2004 to 2011, only 2% of all clear cell, endometriod, and mucinous
ovarian cancer cases were treated with adjuvant RT. Those treated with
RT had a lower CSS and OS at 5-year and 10-year intervals. However,
further subgroup analysis revealed a benefit of RT in terms of OS for
all stage III patients and for stage III patients with mucinous
histology. These findings together with previous studies that
demonstrated a potential survival benefit of adjuvant RT for stage I and
II patients in these histologies suggest a role of RT. Therefore,
further investigation should be performed in the indication for RT, dose
and volume treated, RT techniques and delivery, treatment compliance,
and the patient’s functional status for non-metastatic clear cell,
mucinous, and endometriod ovarian cancer.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.